Healthcare

DaltonTx wins grant for AI-enabled TB drug discovery

DaltonTx received a Gates Foundation grant to use its AI platform in tuberculosis drug discovery.

UK biotechnology company DaltonTx received a Gates Foundation grant to advance tuberculosis drug-discovery programs using its AI-enabled Dalton platform. The funding is directed at applying artificial intelligence to identify and develop potential TB treatments. The announcement concerns drug discovery rather than routine clinical care, but it represents a practical healthcare application of machine learning in a high-need disease area. AI platforms can help researchers prioritize compounds and explore candidate medicines more efficiently than conventional screening alone. The development matters because tuberculosis remains a major global health challenge and drug development can be lengthy and expensive. Grant support may allow DaltonTx to progress its programs and generate evidence for future research and development decisions.

Original source: Pharmaphorum

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI